Vertex Pharma’s $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says

by user

[ad_1]


Vertex Pharmaceuticals Inc.’s $4.9 billion acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company’s rare-disease franchise, analysts said Thursday.

[ad_2]

Source link

Related Posts

Leave a Review

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy